Miconazole Nitrate Add Methanol to Make Exactly 20 Ml, and Use This Solution As the Standard Solution

Total Page:16

File Type:pdf, Size:1020Kb

Miconazole Nitrate Add Methanol to Make Exactly 20 Ml, and Use This Solution As the Standard Solution JP XV O‹cial Monographs / Micronomicin Sulfate 893 sample solution. Pipet 1 mL of the sample solution, add methanol to make exactly 20 mL, pipet 1 mL of this solution, Miconazole Nitrate add methanol to make exactly 20 mL, and use this solution as the standard solution. Perform the test with these solutions ミコナゾール硝酸塩 as directed under Thin-layer Chromatography <2.03>. Spot 50 mL each of the sample solution and standard solution on a plate of silica gel for thin-layer chromatography. Develop the plate with a mixture of n-hexane, chloroform, methanol and ammonia solution (28) (60:30:10:1) to a distance of about 12 cm, and air-dry the plate. Allow the plate in iodine vapor for 20 minutes: the spots other than the principal spot from the sample solution are not more intense than the spot from the standard solution. Loss on drying <2.41> Not more than 0.5z (1 g, in vacuum, C18H14Cl4N2O.HNO3: 479.14 silica gel, 609C, 3 hours). 1-[(2RS)-2-(2,4-Dichlorobenzyloxy)-2-(2,4- Residue on ignition <2.44> Not more than 0.1z (1 g). dichlorophenyl)ethyl]-1H-imidazole mononitrate [22832-87-7 ] Assay Weigh accurately about 0.35 g of Miconazole Ni- trate, previously dried, dissolve in 50 mL of acetic acid (100) Miconazole Nitrate, when dried, contains not less by warming, cool, and titrate <2.50> with 0.1 molWL perchlor- than 98.5z of C18H14Cl4N2O.HNO3. ic acid VS (potentiometric titration). Perform a blank deter- mination, and make any necessary correction. Description Miconazole Nitrate occurs as a white crystal- line powder. Each mL of 0.1 molWL perchloric acid VS It is freely soluble in N,N-dimethylformamide, sparingly = 47.91 mg of C18H14Cl4N2O.HNO3 soluble in methanol, slightly soluble in ethanol (95), in ace- Containers and storage Containers—Tight containers. tone and in acetic acid (100), and very slightly soluble in Storage—Light-resistant. water and in diethyl ether. Melting point: about 1809C (with decomposition). Identiˆcation (1) To 2 mL of a solution of Miconazole Micronomicin Sulfate Nitrate in methanol (1 in 100) add 2 mL of Reinecke salt TS: a light red precipitate is formed. ミクロノマイシン硫酸塩 (2) Determine the absorption spectrum of a solution of Miconazole Nitrate in methanol (1 in 2500) as directed under Ultraviolet-visible Spectrophotometry <2.24>,andcompare the spectrum with the Reference Spectrum: both spectra ex- hibit similar intensities of absorption at the same wavelengths. (3) Perform the test with a solution of Miconazole Ni- trate in methanol (1 in 100) as directed under Flame Colora- tion Test <1.04> (2): a green color appears. (4) A solution of Miconazole Nitrate in methanol (1 in 100) responds to the Qualitative Tests <1.09> for nitrate. Purity (1) Clarity and color of solution—Dissolve 1.0 g of Miconazole Nitrate in 100 mL of methanol: the solution is 1 clear and colorless. C20H41N5O7.2 /2H2SO4:708.77 (2) Chloride <1.03>—Dissolve 0.10 g of Miconazole Ni- 2-Amino-2,3,4,6-tetradeoxy-6-methylamino-a-D- trate in 6 mL of dilute nitric acid and N,N-dimethylfor- erythro-hexopyranosyl-(1ª4)-[3-deoxy-4-C-methyl- mamide to make 50 mL. Perform the test using this solution 3-methylamino-b-L-arabinopyranosyl-(1ª6)]-2-deoxy-D- as the test solution. Prepare the control solution as follows: streptamine hemipentasulfate to 0.25 mL of 0.01 molWL hydrochloric acid VS add 6 mL of [52093-21-7, Micronomicin] dilute nitric acid and N,N-dimethylformamide to make 50 mL (not more than 0.09z). Micronomicin Sulfate is the sulfate of an (3) Heavy metals <1.07>—Proceed with 1.0 g of Micona- aminoglycoside substance having antibacterial activity zole Nitrate according to Method 2, and perform the test. produced by the growth of Micromonospora Prepare the control solution with 1.0 mL of Standard Lead sagamiensis. Solution (not more than 10 ppm). It contains not less than 590 mg (potency) and not (4) Arsenic <1.11>—Prepare the test solution with 1.0 g more than 660 mg (potency) per mg, calculated on the of Miconazole Nitrate according to Method 3, and perform anhydrous basis. The potency of Micronomicin Sulfate the test (not more than 2 ppm). is expressed as mass (potency) of micronomicin (5) Related substances—Dissolve 0.10 g of Miconazole (C20H41N5O7:463.57). Nitrate in 10 mL of methanol, and use this solution as the Description Micronomicin Sulfate occurs as a white to light 894 Midecamycin / O‹cial Monographs JP XV yellowish white powder. er. It is very soluble in water, sparingly soluble in ethylene (iii) Standard solutions—Weigh accurately an amount of glycol, and practically insoluble in methanol and in ethanol Micronomicin Sulfate Reference Standard, equivalent to (99.5). about 20 mg (potency), dissolve in 0.1 mol/L phosphate It is hygroscopic. buŠer solution for antibiotics, pH 8.0 to make exactly 20 mL, and use this solution as the standard stock solution. Identiˆcation (1) Dissolve 50 mg each of Micronomicin Keep the standard stock solution at 5 – 159C, and use within Sulfate and Micronomicin Sulfate Reference Standard in 10 30 days. Take exactly a suitable amount of the standard stock mL of water, and use these solutions as the sample solution solution before use, add 0.1 mol/L phosphate buŠer solution and the standard solution. Perform the test with these solu- for antibiotics, pH 8.0 to make solutions so that each mL tions as directed under Thin-layer Chromatography <2.03>. contains 2 mg (potency) and 0.5 mg (potency), and use these Spot 5 mL of the sample solution and standard solution on a solutions as the high concentration standard solution and low plate of silica gel for thin-layer chromatography. Develop the concentration standard solution, respectively. plate with a mixture of ethanol (99.5), 1-buthanol and ammo- (iv) Sample solutions—Weigh accurately an amount of nia solution (28) (10:8:7) to a distance of about 10 cm, and Micronomicin Sulfate, equivalent to about 20 mg (potency), air-dry the plate. Spray evenly a solution of ninhydrin in a and dissolve in 0.1 mol/L phosphate buŠer solution for an- mixture of acetone and pyridine (25:1) (1 in 500), and heat at tibiotics, pH 8.0 to make exactly 20 mL. Take exactly a suita- 1009C for 10 minutes: the spots obtained from the sample so- ble amount of this solution, add 0.1 mol/L phosphate buŠer lution and the standard solution are red-purple to red-brown solution for antibiotics, pH 8.0 to make solutions so that and their Rfvaluesarethesame. each mL contains 2 mg (potency) and 0.5 mg (potency), and (2) To 5 mL of a solution of Micronomicin Sulfate (1 in use these solutions as the high concentration sample solution 100) add 1 mL of barium chloride TS: a white precipitate is and low concentration sample solution, respectively. formed, and it does not dissolve by addition of dilute nitric acid. Containers and storage Containers—Tight containers. 20 Optical rotation <2.49> [a]D : +110 – +1309(0.25 g calcu- lated on the anhydrous basis, water, 25 mL, 100 mm). Midecamycin pH <2.54> The pH of a solution obtained by dissolving 1.0 g of Micronomicin Sulfate in 10 mL of water is between 3.5 ミデカマイシン and 5.5. Purity (1) Clarity and color of solution—Dissolve 1.5 g of Micronomicin Sulfate in 10 mL of water: the solution is clear and colorless to pale yellow. (2) Heavy metals <1.07>—Proceed with 1.0 g of Micronomicin Sulfate according to Method 2, and perform the test. Prepare the control solution with 2.0 mL of Stan- dard Lead Solution (not more than 20 ppm). (3) Related substances—Dissolve 0.40 g of Micronomicin Sulfate in 10 mL of water, and use this solution as the sample solution. Pipet 1 mL of the sample solution, add water to make exactly 200 mL, and use this solution as the standard solution. Perform the test with these solutions as directed un- der Thin-layer Chromatography <2.03>.Spot5mLofthe C H NO :813.97 samplesolutionandstandardsolutiononaplateofsilicagel 41 67 15 (3 ,4 ,5 ,6 ,8 ,9 ,10 ,12 ,15 )- for thin-layer chromatography. Develop the plate with a mix- R R S R R R E E R 5-[2,6-Dideoxy-3-C-methyl-4-O-propanoyl-a-L-ribo- ture of ethanol (99.5), 1-buthanol and ammonia solution (28) hexopyranosyl-(1 4)-3,6-dideoxy-3-dimethylamino- -D- (10:8:7) to a distance of about 10 cm, and air-dry the plate. ª b glucopyranosyloxy]-6-formylmethyl-9-hydroxy-4-methoxy- Spray evenly a solution of ninhydrin in a mixture of acetone 8-methyl-3-propanoyloxyhexadeca-10,12-dien-15-olide and pyridine (25:1) (1 in 500), and heat at 1009Cfor10 [ ] minutes: the spot other than the principal spot obtained from 35457-80-8 the sample solution is not more intense than the spot from the standard solution. Midecamycin is a macrolide substance having an- tibacterial activity produced by the growth of Strep- Water <2.48> Not more than 10.0z (0.2 g, volumetric titra- tomyces mycarofaciens. tion, back titration). Use a mixture of methanol for water de- It contains not less than 950 mg (potency) and not termination and ethylene glycol for water determination (1:1) more than 1020 mg (potency) per mg, calculated on the instead of methanol for water determination. dried basis. The potency of Midecamycin is expressed Assay Perform the test according to the Cylinder-plate as mass (potency) of midecamycin (C41H67NO15).
Recommended publications
  • Pharmaceutical Microbiology Table of Contents
    TM Pharmaceutical Microbiology Table of Contents Pharmaceutical Microbiology ������������������������������������������������������������������������������������������������������������������������ 1 Strains specified by official microbial assays ������������������������������������������������������������������������������������������������ 2 United States Pharmacopeia (USP) �������������������������������������������������������������������������������������������������������������������������������������������2 European Pharmacopeia (EP) Edition 8�1 ���������������������������������������������������������������������������������������������������������������������������������5 Japanese Pharmacopeia (JP) ������������������������������������������������������������������������������������������������������������������������������������������������������7 Strains listed by genus and species �������������������������������������������������������������������������������������������������������������10 ATCC provides research and development tools and reagents as well as related biological material management services, consistent with its mission: to acquire, authenticate, preserve, develop, and distribute standard reference THE ESSENTIALS microorganisms, cell lines, and related materials for research in the life sciences� OF LIFE SCIENCE For over 85 years, ATCC has been a leading authenticate and further develop products provider of high-quality biological materials and services essential to the needs of basic and standards to the life
    [Show full text]
  • Nature Nurtures the Design of New Semi-Synthetic Macrolide Antibiotics
    The Journal of Antibiotics (2017) 70, 527–533 OPEN Official journal of the Japan Antibiotics Research Association www.nature.com/ja REVIEW ARTICLE Nature nurtures the design of new semi-synthetic macrolide antibiotics Prabhavathi Fernandes, Evan Martens and David Pereira Erythromycin and its analogs are used to treat respiratory tract and other infections. The broad use of these antibiotics during the last 5 decades has led to resistance that can range from 20% to over 70% in certain parts of the world. Efforts to find macrolides that were active against macrolide-resistant strains led to the development of erythromycin analogs with alkyl-aryl side chains that mimicked the sugar side chain of 16-membered macrolides, such as tylosin. Further modifications were made to improve the potency of these molecules by removal of the cladinose sugar to obtain a smaller molecule, a modification that was learned from an older macrolide, pikromycin. A keto group was introduced after removal of the cladinose sugar to make the new ketolide subclass. Only one ketolide, telithromycin, received marketing authorization but because of severe adverse events, it is no longer widely used. Failure to identify the structure-relationship responsible for this clinical toxicity led to discontinuation of many ketolides that were in development. One that did complete clinical development, cethromycin, did not meet clinical efficacy criteria and therefore did not receive marketing approval. Work on developing new macrolides was re-initiated after showing that inhibition of nicotinic acetylcholine receptors by the imidazolyl-pyridine moiety on the side chain of telithromycin was likely responsible for the severe adverse events.
    [Show full text]
  • WO 2016/120258 Al O
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2016/120258 A l 4 August 2016 (04.08.2016) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/00 (2006.01) A61K 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/20 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP20 16/05 1545 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, 26 January 2016 (26.01 .2016) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 264/MUM/2015 27 January 2015 (27.01 .2015) IN kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: JANSSEN PHARMACEUTICA NV TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, [BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).
    [Show full text]
  • US 2002/0071822 A1 Uhrich (43) Pub
    US 20020071822A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0071822 A1 Uhrich (43) Pub. Date: Jun. 13, 2002 (54) THERAPEUTIC POLYESTERS AND provisional application No. 60/261,337, filed on Jan. POLYAMIDES 12, 2001. (76) Inventor: Kathryn E. Uhrich, Hoboken, NJ (US) Publication Classification Correspondence Address: (51) Int. Cl." ..................... A61K 31/785; A61K 31/765; SCHWEGMAN, LUNDBERG, WOESSNER & C08G 63/685; CO8G 63/688 KLUTH, PA. (52) U.S. Cl. ....................... 424/78.37; 528/288; 528/293 P.O. BOX 2938 MINNEAPOLIS, MN 55402 (US) (57) ABSTRACT (21) Appl. No.: 09/917,194 Polymers (i.e. polyesters, polyamides, and polythioesters or (22) Filed: Jul. 27, 2001 a mixture thereof) which degrade hydrolytically into bio logically active compounds are provided. Methods of pro Related U.S. Application Data ducing these polymers, intermediates useful for preparing these polymers, and methods of using these polymers to (63) Non-provisional of provisional application No. deliver biologically active compounds to a host are also 60/220,707, filed on Jul. 27, 2000. Non-provisional of provided. US 2002/0071822 A1 Jun. 13, 2002 THERAPEUTIC POLYESTERS AND POLYAMDES 0012. The invention also provides processes and inter mediates disclosed herein that are useful for preparing a PRIORITY OF INVENTION polymer of the invention. 0001. This application claims priority from U.S. Provi DETAILED DESCRIPTION OF THE sional Application No. 60/220,707, filed Jul. 27, 2000 and INVENTION U.S. Provisional Application No. 60/261,337, filed Dec. 1, 2001, which are incorporated herein by reference. 0013 Definitions 0014. The following definitions are used, unless other BACKGROUND OF THE INVENTION wise described: halo is fluoro, chloro, bromo, or iodo.
    [Show full text]
  • Effects of Chlortetracycline and Copper Supplementation on Levels of Antimicrobial Resistance in the Feces of Weaned Pigs
    EFFECTS OF CHLORTETRACYCLINE AND COPPER SUPPLEMENTATION ON LEVELS OF ANTIMICROBIAL RESISTANCE IN THE FECES OF WEANED PIGS by GETAHUN EJETA AGGA DVM, Addis Ababa University, 2003 MSc, Utrecht University, 2008 AN ABSTRACT OF A DISSERTATION submitted in partial fulfillment of the requirements for the degree DOCTOR OF PHILOSOPHY Department of Diagnostic Medicine/Pathobiology College of Veterinary Medicine KANSAS STATE UNIVERSITY Manhattan, Kansas 2013 Abstract The use of antibiotics in food animals is of major concern as a purported cause of antimicrobial resistance (AMR) in human pathogens; as a result, alternatives to in-feed antibiotics such as heavy metals have been proposed. The effect of copper and CTC supplementation in weaned pigs on AMR in the gut microbiota was evaluated. Four treatment groups: control, copper, chlortetracycline (CTC), and copper plus CTC were randomly allocated to 32 pens with five pigs per pen. Fecal samples (n = 576) were collected weekly from three pigs per pen over six weeks and two Escherichia coli isolates per sample were tested phenotypically for antimicrobial and copper susceptibilities and genotypically for the presence of tetracycline (tet), copper (pcoD) and ceftiofur (blaCMY-2) resistance genes. CTC-supplementation significantly increased tetracycline resistance and susceptibility to copper when compared with the control group. Copper supplementation decreased resistance to most of the antibiotics, including cephalosporins, over all treatment periods. However, copper supplementation did not affect minimum inhibitory concentrations of copper or detection of pcoD. While tetA and blaCMY-2 genes were associated with a higher multi-drug resistance (MDR), tetB and pcoD were associated with lower MDR. Supplementations of CTC or copper alone were associated with increased tetB prevalence; however, their combination was paradoxically associated with reduced prevalence.
    [Show full text]
  • Surveillance of Antimicrobial Consumption in Europe 2013-2014 SURVEILLANCE REPORT
    SURVEILLANCE REPORT SURVEILLANCE REPORT Surveillance of antimicrobial consumption in Europe in Europe consumption of antimicrobial Surveillance Surveillance of antimicrobial consumption in Europe 2013-2014 2012 www.ecdc.europa.eu ECDC SURVEILLANCE REPORT Surveillance of antimicrobial consumption in Europe 2013–2014 This report of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Klaus Weist. Contributing authors Klaus Weist, Arno Muller, Ana Hoxha, Vera Vlahović-Palčevski, Christelle Elias, Dominique Monnet and Ole Heuer. Data analysis: Klaus Weist, Arno Muller and Ana Hoxha. Acknowledgements The authors would like to thank the ESAC-Net Disease Network Coordination Committee members (Marcel Bruch, Philippe Cavalié, Herman Goossens, Jenny Hellman, Susan Hopkins, Stephanie Natsch, Anna Olczak-Pienkowska, Ajay Oza, Arjana Tambić Andrasevic, Peter Zarb) and observers (Jane Robertson, Arno Muller, Mike Sharland, Theo Verheij) for providing valuable comments and scientific advice during the production of the report. All ESAC-Net participants and National Coordinators are acknowledged for providing data and valuable comments on this report. The authors also acknowledge Gaetan Guyodo, Catalin Albu and Anna Renau-Rosell for managing the data and providing technical support to the participating countries. Suggested citation: European Centre for Disease Prevention and Control. Surveillance of antimicrobial consumption in Europe, 2013‒2014. Stockholm: ECDC; 2018. Stockholm, May 2018 ISBN 978-92-9498-187-5 ISSN 2315-0955
    [Show full text]
  • T Genetic Name of Midecamycin Acetate(MOM)
    1086 THE JOURNAL OF ANTIBIOTICS AUG.198Z SYNERGISTIC EFFECTS OF A MACROLiDE AND A CELL WALL-AFFECTING ANTIBIOTIC ON PSEUDOMONAS AERUGINOSA IN VITRO AND IN VIVO 3.INCORPORATION OF[14C]MIDECAMYCIN ACETATE(MOM)† INTO P.AERUGINOSA PRETREATED WITH CELL WALL-AFFECTING. ANTIBIOTICS TAKAo KAsAI,*TosHlo ToMITA, SHIRo KANEGAsAKI and J, YuzuRu HoMMA** Department of Bacteriology,Institute of Medical Science, Universityof Tokyo, Shiroganedai, Minato-ku, Tokyo lO8, Japan (Received for publicatioll April l7,1982) Thc occurrence inρ 一lactam treated patiellts of unstable L-forms of Pseudomonas aeruginosa hlscnsitivc to various antibiotics and synergistic effect ofcombined action of celi wa11-affecting antibiotics and macrolide on Pseudomonas infection led us to examine thc effects of macrolidc on P.aeruginosa pretreated with cell wail-affbcting antibiotics. The effects of macrolide antibiotics such as midecamycin acetate(MOM)on P. aeruginosa was investigated, a rapid killing effect by MOM was lloted after treatmellt wkh suboptimal doses of ce11 wa11-affecting antibiotics such as polymyxin B, carbenicillin, dibekacill or fosfomycin. IIlcorporation of [1.4C]MOM lllto intact P.aeruginosa cells was not significant, but was apparent into L-form cells or cells pretreated wiIh cell wall-affecting antibiotics, The incor- porated radioactlvity was found in thc 70 S ribosome fractio11, binding with the 50 S subunits of ribosome in both cases, These results indicate tllat under certain conditions a macrolidc antibiotic can emer the P.aeruginosa cell, YAMAMoTo and HoMMA1)reported isolating unstable L-forms from clinical specimens of patients with chronic respiratory tract infection and cow mastitis due to P.aeruginosa who were undergoingβ 一 l actanl antibiotic therapy.
    [Show full text]
  • Antibiotics and Antibiotic Resistance
    This is a free sample of content from Antibiotics and Antibiotic Resistance. Click here for more information on how to buy the book. Index A Antifolates. See also specific drugs AAC(60)-Ib-cr, 185 novel compounds, 378–379 ACHN-975 overview, 373–374 clinical studies, 163–164 resistance mechanisms medicinal chemistry, 166 sulfamethoxazole, 378 structure, 162 trimethoprim, 374–378 AcrAB-TolC, 180 Apramycin, structure, 230 AcrD, 236 Arbekacin, 237–238 AdeRS, 257 Avibactam, structure, 38 AFN-1252 Azithromycin mechanism of action, 148, 153 resistance, 291, 295 resistance, 153 structure, 272 structure, 149 Aztreonam, structure, 36 AIM-1, 74 Amicoumacin A, 222 Amikacin B indications, 240 BaeSR, 257 structure, 230 BAL30072, 36 synthesis, 4 BB-78495, 162 Aminoglycosides. See also specific drugs BC-3205, 341, 344 historical perspective, 229–230 BC-7013, 341, 344 indications, 239–241 b-Lactamase. See also specific enzymes mechanism of action, 232 classification novel drugs, 237 class A, 67–71 pharmacodynamics, 238–239 class B, 69–74 pharmacokinetics, 238–239 class C, 69, 74 resistance mechanisms class D, 70, 74–77 aminoglycoside-modifying enzymes evolution of antibiotic resistance, 4 acetyltransferases, 233–235 historical perspective, 67 nucleotidyltransferases, 235 inhibitors phosphotransferases, 235 overview, 37–39 efflux-mediated resistance, 236 structures, 38 molecular epidemiology, 236–237 nomenclature, 67 overview, 17, 233 b-Lactams. See also specific classes and antibiotics ribosomal RNA modifications, 235–236 Enterococcus faecium–resistancemechanisms,
    [Show full text]
  • Zebrafish As a Screening Model to Study the Single and Joint Effects Of
    pharmaceuticals Review Zebrafish as a Screening Model to Study the Single and Joint Effects of Antibiotics † Roxana Jijie 1,2,*,‡, Gabriela Mihalache 3,4,‡, Ioana-Miruna Balmus 2, Stefan-Adrian Strungaru 2 , Emanuel Stefan Baltag 1 , Alin Ciobica 5, Mircea Nicoara 5,6 and Caterina Faggio 7,* 1 Marine Biological Station “Prof. dr. I. Borcea”, “Alexandru Ioan Cuza” University of Iasi, Nicolae Titulescu Street, No. 163, 9007018 Agigea, Romania; [email protected] 2 Department of Exact and Natural Sciences, Institute of Interdisciplinary Research, “Alexandru Ioan Cuza” University of Iasi, 11 Carol I, 700506 Iasi, Romania; [email protected] (I.-M.B.); [email protected] (S.-A.S.) 3 Integrated Center of Environmental Science Studies in the North Eastern Region (CERNESIM), “Alexandru Ioan Cuza” University of Iasi, 11 Carol I, 700506 Iasi, Romania; [email protected] 4 Department of Horticultural Technologies, “Ion Ionescu de la Brad” University of Agricultural Sciences and Veterinary Medicine, 700440 Iasi, Romania 5 Department of Biology, Faculty of Biology, “Alexandru Ioan Cuza” University of Iasi, B-dul Carol I, 700505 Iasi, Romania; [email protected] (A.C.); [email protected] (M.N.) 6 Doctoral School of Geosciences, Faculty of Geography-Geology, “Alexandru Ioan Cuza” University of Iasi, B-dul Carol I, 700505 Iasi, Romania 7 Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale F. Stagno, d’Alcontres, 31 98166 S. Agata-Messina, Italy * Correspondence: [email protected] (R.J.); [email protected] (C.F.) † This paper is dedicated to the memory of Stefan-Adrian Strungaru, colleague, researcher and friend, who prematurely passed away in April 2021.
    [Show full text]
  • Development of Novel Antibiotic Classes
    60 years ago… The changes in antibiotic research as shown by patent publications Development of Novel Antibiotic Classes 1930 1940 1950 1960 1970 1980 1990 2000 2003 Daptomycin 1999 Linezolid 1962 Quinolones 1962 Streptogramins 1958 Glycopeptides 1952 Macrolides 1950 Aminoglycosides 1949 Chloramphenicol 1949 Tetracyclines 1940 Beta-Lactams 1936 Sulfonamides Harald Labischinski Products in the Pipeline Product Class Main Segment Status ABT 492 Quinolone Community Ph II DK507k Quinolone Community Ph I Daptomycin Lipopeptide Hospital Reg. Oritavancin Glycopeptide Hospital Ph III Dalbavancin Glycopeptide Hospital Ph III Tigecycline Glycylcycline Hospital Ph III AR 100 Trimethoprime Hospital Ph II BAL 9141 Cephalosporin Hospital Ph II BB-83698 PDF-inhibitor Community Ph I CS-023 Carbapenem Hospital Ph II Until 2008 very few antibiotics will reach the market ! Harald Labischinski 60 years ago… 1942 Gardner and Chain discover a substance with antibacterial activity, produced by a strain of Proactinomyces (later Streptomyces gardneri), which they name proactinomycin A. Macrolide structure • Macrolides are lipophilic molecules with a characteristic central lactone ring bearing 12 to 17 atoms, few if any double bonds and no nitrogen athoms (until the advent of the azalides). • Several amino and/or neutral sugars can bind to the lactone ring. MACROLIDE ANTIBIOTICS 12-membered-ring 14-membered-ring 15-membered-ring 16-membered-ring 17-membered-ring Methymycin Natural Semi-synthetic Azithromycin Natural Semi-synthetic Lankacidin Neomethymycin compounds derivatives compounds derivatives complex YC-17 Litorin Erythromycin A to F Roxithromycin Josamycin Rokitamycin Oleandomycin Dirithromycin Kitasamycin Miokamycin Sporeamicin Flurithromycin Spiramycin Clarithromycin Midecamycin • The macrolides narrow the entrance of the tunnel through which the nascent polypeptide chain is extruded from the ribosome.
    [Show full text]
  • WHO Report on Surveillance of Antibiotic Consumption: 2016-2018 Early Implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some Rights Reserved
    WHO Report on Surveillance of Antibiotic Consumption 2016-2018 Early implementation WHO Report on Surveillance of Antibiotic Consumption 2016 - 2018 Early implementation WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation ISBN 978-92-4-151488-0 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution- NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons. org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non- commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. WHO report on surveillance of antibiotic consumption: 2016-2018 early implementation. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]